SCHEMBL7400413

SCHEMBL7400413

O=C(O)[C@@H]1CNCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8164385 1.00
SCHEMBL337118 1.00
Hydrochloric Acid SCHEMBL16095751 0.98 SSTR4 (0.47)
SCHEMBL27595403 0.98 SSTR4 (0.47)
Hydrochloric Acid SCHEMBL16094440 0.98 SSTR4 (0.47)
Hydrochloric Acid SCHEMBL1609138 0.98 SSTR4 (0.47)
Trifluoroacetic Acid SCHEMBL19551067 0.89 SSTR4 (0.46)
SCHEMBL24502684 0.87 SLC6A1 (0.45)
SCHEMBL30194780 0.87 SLC6A1 (0.45)
SCHEMBL30987164 0.85 SLC6A1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12024506-B2 Compounds THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-07-02 US claimed
EP-3743421-B1 COMPOUNDS UNIV OXFORD INNOVATION LTD (GB) 2023-03-29 EP claimed
US-20210009576-A1 COMPOUNDS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-01-14 US claimed
EP-3743421-A1 COMPOUNDS Oxford University Innovation Limited (GB) 2020-12-02 EP claimed
WO-2019145718-A1 COMPOUNDS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2019-08-01 WO claimed
EP-2616070-B1 NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS AETERNA ZENTARIS GMBH (DE) 2018-02-14 EP claimed
US-8546435-B2 Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors AETERNA ZENTARIS GMBH (DE) 2013-10-01 US claimed
EP-2616070-A1 NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS Æterna Zentaris GmbH (DE) 2013-07-24 EP claimed
WO-2012035124-A1 NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS ÆTERNA ZENTARIS GMBH (DE) 2012-03-22 WO claimed
US-20250345341-A1 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament BOEHRINGER INGELHEIM INT (DE) 2025-11-13 US disclosed
EP-4572759-A2 THIAZOLE DERIVATIVES FOR THERAPEUTIC USE Nimml Institute (US) 2025-06-25 EP disclosed
US-20240376099-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2024-11-14 US disclosed
US-20240246978-A1 PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF Hepagene Therapeutics (HK) Limited (CN) 2024-07-25 US disclosed
US-12024506-B2 Compounds THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-07-02 US disclosed
US-5955433-A DERIVATIVES OF B-CYCLOHEXYLALANINE-PROLINE-AGMATINE ARE ADMINISTERED AS ANTICOAGULANTS ASTRA AKTIEBOLAG (SE) 1999-09-21 US disclosed
US-5747460-A Method of treatment and prophylaxis of venous thrombosis ASTRA AKTIEBOLAG (SE) 1998-05-05 US disclosed
US-5736521-A ADMINISTERING AMINO ACID COMPOUND ASTRA AKTIEBOLAG (SE) 1998-04-07 US disclosed
US-5614499-A ANTICOAGULANTS; TREATMENT OR PROPHYLAXIS OF THROMBOSIS ASTRA AKTIEBOLAG (SE) 1997-03-25 US disclosed
EP-0618926-A1 NEW PEPTIDE DERIVATIVES Astra Aktiebolag (SE) 1994-10-12 EP disclosed
WO-1993011152-A1 NEW PEPTIDE DERIVATIVES AKTIEBOLAGET ASTRA (SE) 1993-06-10 WO disclosed